Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Schizophrenia and major depressive disorder (MDD) are disabling psychiatric conditions that are linked to a heavy economic and disease burden on society and patients as well as their caregivers. Antipsychotics (older typical or newer atypical antipsychotics) are the standard of care for schizophrenia, and they are also used among treatment-resistant MDD patients. In an overgenericized market of well-established, mostly reimbursed key agents, psychiatrists may be reluctant to switch to newer and more expensive treatment options. However, high unmet need remains for therapies with demonstrated efficacy for both conditions. In this Access & Reimbursement analysis, we discuss the current access landscape for antipsychotics in China, with a focus on atypical antipsychotics’ use in schizophrenia and MDD. In addition, we analyze the future uptake of emerging therapies (e.g., Sumitomo Dainippon’s Latuda) and pinpoint the levers and roadblocks to their success.
Already a Client? Log in to access this report.
Based in DRG’s Hong Kong office, Michael analyses the evolving market access landscape in the Asia-Pacific region, including Australia, China, Japan, South Korea, The Philippines, and Taiwan. Michael is also responsible for market research and sales forecast in China among key therapeutic areas including diabetes. Michael previously worked as a health economics and outcome research consultant in Tokyo. Michael completed his Master degree in International Health Policy at London School of Economics and has a degree in Biochemistry from Imperial College London.